이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

뼈 전이가 있는 진행성 전립선암 남성에게 라듐-223을 투여한 다양한 용량의 올라파립의 안전성 테스트

2026년 11월 11일 업데이트: National Cancer Institute (NCI)

뼈 전이가 있는 전이성 거세 저항성 전립선암이 있는 남성을 대상으로 올라파립과 라듐-223의 조합에 대한 1/2상 연구(COMRADE)

This phase I/II trial studies the best dose and side effects of olaparib and how well it works with radium Ra 223 dichloride in treating patients with castration-resistant prostate cancer that has spread to the bone and other places in the body (metastatic). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radioactive drugs, such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm normal cells. Giving olaparib and radium Ra 223 dichloride may help treat patients with castration-resistant prostate cancer.

연구 개요

상태

모집하지 않고 적극적으로

정황

개입 / 치료

상세 설명

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase I) II. Evaluate the radiographic progression-free survival (rPFS). (Phase II)

SECONDARY OBJECTIVES:

I. Evaluate safety and tolerability as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

II. To evaluate rPFS as stratified by disease extent (=< 20 or > 20 bone lesions) and prior docetaxel use (yes or no).

III. Evaluate rPFS in patients harboring or lacking evidence of homologous recombination deficiency (HRD).

IV. Evaluate rPFS in patients based on prior abiraterone and/or next generation androgen receptor (AR) antagonist (enzalutamide, apalutamide, darolutamide or other agent) use (yes versus no) for either hormone sensitive or castration resistant prostate cancer (CRPC).

V. Evaluate prostate specific antigen (PSA) response rate as defined by >= 50% decline in PSA from baseline.

VI. Evaluate total alkaline phosphatase response defined as a reduction of >= 30% from the baseline value, confirmed >= 4 weeks later.

VII. Evaluate time to PSA progression as defined by Prostate Cancer Clinical Trials Working Group (PCTWG) 3 criteria.

VIII. Evaluate radiographic objective response rate as defined by Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1.

IX. Evaluate time to increase in the total alkaline phosphatase (ALP) level defined as an increase of >= 25% from baseline at >= 12 weeks, in patients with no decrease from baseline, or as an increase of >= 25% above the nadir, confirmed >= 3 weeks later, in patients with an initial decrease from baseline.

X. Evaluate time to first subsequent anti-cancer therapy (including AR signaling agents, cytotoxic chemotherapy, immunotherapy, or investigational agents) or death.

XI. Evaluate time to first symptomatic skeletal event (SSE). XII. Evaluate overall survival (OS).

EXPLORATORY OBJECTIVES:

I. Evaluate impact on quality of life (QOL) as determined by Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and Brief Pain Inventory (BPI).

II. Estimate the frequency of mutations in the deoxyribonucleic acid (DNA) repair pathway in patients with metastatic castration-resistant prostate cancer (CRPC) as determine by Oncopanel testing and by whole exome sequencing (WES).

III. Characterize changes in ribonucleic acid (RNA) expression of DNA repair genes and immune markers by whole transcriptome sequencing (WTS) in each arm.

IV. Characterize changes in immune cell, T-cell receptor (TCR), and B-cell (BCR) receptor repertoire at baseline, during treatment, and at progression in each arm.

V. Evaluate changes in lactate dehydrogenase (LDH) in patients each treatment arm.

VI. Assess the prevalence of germline mutations in homologous recombination genes in all enrolled patients.

VII. Correlate homologous recombination gene germline mutation status with PSA response by treatment arm.

VIII. Evaluate family history of cancers in the study population and correlate family cancer history with germline mutation status.

IX. Correlate presence or absence of RAD51 with somatic and germline homologous recombination gene mutation status, PSA response, and PFS between treatment arms.

X. Evaluate the changes in whole genome sequencing (WGS) of plasma cell-free circulating DNA (cfDNA) based patient-tumor specific signature at baseline, on treatment, and at progression.

XI. Evaluate tumor mutation burden (TMB) and tumor mutational signature in plasma cfDNA at baseline and correlate to tumor tissue TMB and mutational signature.

OUTLINE: This is a phase I, dose-escalation study of olaparib followed by a phase II study.

PHASE I: Patients receive radium Ra 223 dichloride intravenously (IV) over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib orally (PO) twice daily (BID) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo computed tomography (CT) or magnetic resonance imaging (MRI) as well as blood sample collection and a tissue biopsy during screening and on study.

PHASE II: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

ARM II: Patients receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

After completion of study treatment, patients are followed up every 6 months for 2 years.

연구 유형

중재적

등록 (실제)

132

단계

  • 2 단계
  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • La Jolla, California, 미국, 92093
        • UC San Diego Moores Cancer Center
      • Sacramento, California, 미국, 95817
        • University of California Davis Comprehensive Cancer Center
    • Connecticut
      • New Haven, Connecticut, 미국, 06520
        • Yale University
      • New Haven, Connecticut, 미국, 06510
        • Smilow Cancer Center/Yale-New Haven Hospital
    • Kansas
      • Fairway, Kansas, 미국, 66205
        • University of Kansas Clinical Research Center
      • Kansas City, Kansas, 미국, 66160
        • University of Kansas Cancer Center
      • Overland Park, Kansas, 미국, 66210
        • University of Kansas Cancer Center-Overland Park
      • Westwood, Kansas, 미국, 66205
        • University of Kansas Hospital-Westwood Cancer Center
    • Maryland
      • Baltimore, Maryland, 미국, 21201
        • University of Maryland/Greenebaum Cancer Center
    • Michigan
      • Detroit, Michigan, 미국, 48201
        • Wayne State University/Karmanos Cancer Institute
    • Missouri
      • City of Saint Peters, Missouri, 미국, 63376
        • Siteman Cancer Center at Saint Peters Hospital
      • Creve Coeur, Missouri, 미국, 63141
        • Siteman Cancer Center at West County Hospital
      • Kansas City, Missouri, 미국, 64154
        • University of Kansas Cancer Center - North
      • Lee's Summit, Missouri, 미국, 64064
        • University of Kansas Cancer Center - Lee's Summit
      • North Kansas City, Missouri, 미국, 64116
        • University of Kansas Cancer Center at North Kansas City Hospital
      • St Louis, Missouri, 미국, 63110
        • Washington University School of Medicine
      • St Louis, Missouri, 미국, 63129
        • Siteman Cancer Center-South County
    • New Jersey
      • New Brunswick, New Jersey, 미국, 08903
        • Rutgers Cancer Institute of New Jersey
    • North Carolina
      • Durham, North Carolina, 미국, 27710
        • Duke University Medical Center
    • Ohio
      • Columbus, Ohio, 미국, 43210
        • Ohio State University Comprehensive Cancer Center
    • Pennsylvania
      • Pittsburgh, Pennsylvania, 미국, 15232
        • UPMC Hillman Cancer Center
    • Wisconsin
      • Madison, Wisconsin, 미국, 53792
        • University of Wisconsin Carbone Cancer Center - University Hospital

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

남성

설명

Inclusion Criteria:

  • Participants must be male aged >= 18 years of age

  • Participants must have histologically or cytologically confirmed adenocarcinoma of the prostate

  • Participants must have castrate levels of serum testosterone < 50 ng/dL

  • Participants without orchiectomy must be maintained on luteinizing hormone releasing hormone (LHRH) agonist/antagonist; participants receiving prior docetaxel abiraterone, or next generation AR antagonist (enzalutamide, apalutamide, or darolutamide) for hormone sensitive disease are permitted

  • Participants must have progressive disease as defined by any of the following:

    • Castrate resistant disease as defined by PCWG-3 criteria; participants must have a rise in PSA on two successive determination at least one week apart and PSA levels >= 2 ng/mL (only the screening PS needs to be >= 2 ng/mL) and serum testosterone < 50 ng/dL
    • Soft tissue progression as defined by RECIST version 1.1
    • Bone disease progression as defined by PCWG-3 criteria including the development of two or more new lesions on bone scan
  • Participants must have >= 2 bone metastases by radiographic imaging and at least 1 lesion which has not been treated with prior radiation therapy

  • Participants must have tumor accessible for biopsy and be agreeable to baseline tumor biopsy; a metastatic focus is preferred but if not available and prostate is still intact prostate biopsy can be performed

  • Availability at the study site of formalin-fixed, paraffin-embedded (FFPE) archival tumor specimens, when available

  • Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 80%)

  • White blood cell count (WBC) >= 3,000/mcL (within 28 days prior to administration of study treatment)

  • Absolute neutrophil count (ANC) >= 1,500/mcL (within 28 days prior to administration of study treatment)

  • Platelets >= 100,000/mcL (within 28 days prior to administration of study treatment)

  • Hemoglobin >= 10 g/dL (transfusions permitted) (within 28 days prior to administration of study treatment)

  • Total bilirubin =< 1.5 x the institutional upper limit of normal (ULN) (within 28 days prior to administration of study treatment); for subjects with Gilbert's disease =< 3.0 mg/dL

  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x institutional ULN (within 28 days prior to administration of study treatment)

  • Creatinine clearance >= 51 ml/min as defined by Cockcroft-Gault equation (within 28 days prior to administration of study treatment)

  • Participants should be receiving an osteoclast targeting agent including either bisphosphonates or denosumab except in patients with contraindications as determined by the treating investigator including:

    • Hypocalcemia
    • Hypophosphatemia
    • Renal impairment including those with a glomerular filtration rate < 35 mL/min using the Cockcroft-Gault equation
    • Hypersensitivity to drug formulation
    • Dental condition or need for dental intervention that per the investigator would increase the risk of osteonecrosis of the jaw
  • The effects of olaparib and radium-223 on the developing human fetus are unknown; for this reason, men treated or enrolled on this protocol must agree to use adequate contraception and avoid sperm donation prior to the study, for the duration of study participation, and three months after discontinuation of olaparib and radium-223 administration

  • Human immunodeficiency virus (HIV)-positive with negative viral loads on stable antiretroviral regimen and CD4 count > 250 are eligible

  • Ability to understand and the willingness to sign a written informed consent document; patients with impaired decision-making who have a legal guardian (e.g., spouse) able to make informed decisions on behalf of the patient are eligible

  • Patients must be able to tolerate oral medications by mouth and not have a gastrointestinal illness that would preclude absorption of olaparib

Exclusion Criteria:

  • Pathology consistent with small cell carcinoma of the prostate

  • Presence of visceral metastases (liver, lung, brain, etc.) or malignant lymphadenopathy exceeding 4 centimeters (cm) in short diameter

  • Prior treatment with radium-223

  • Prior treatment with olaparib or other PARPi

  • Treatment with abiraterone, apalutamide, or darolutamide within 2 weeks of treatment initiation; treatment with cytotoxic chemotherapy within 3 weeks of treatment initiation; treatment with investigational prostate cancer directed therapy within 4 weeks of treatment initiation; treatment with enzalutamide within 4 weeks of treatment initiation

  • Prior hemibody external radiotherapy

  • Palliative radiation therapy to the bone or other sites within 2 weeks of treatment initiation

  • Participants who are receiving any other investigational agents

  • Imminent or established spinal cord compression based on clinical and/or imaging findings

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring need for intravenous anti-microbials, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

  • Clinically significant medical condition defined as:

    • Cerebral infarction within 6 months of study treatment
    • Transient ischemic attack within 3 months of study treatment
    • Myocardial infarction within 6 months of study treatment
    • Uncontrolled angina within 3 months of study treatment
    • Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan performed within 3 months of the screening visit results in a left ventricular ejection fraction that is >= 45%
    • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes)
    • Prolonged corrected QT interval by the Fridericia correction formula on the screening electrocardiogram (ECG) > 470 msec (as determined on 2 or more time points within a 24 hour period if the first ECG demonstrates a prolonged corrected QT interval) or family history of long QT syndrome
    • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
    • Uncontrolled hypertension as indicated by a resting systolic blood pressure > 170 mmHg or diastolic blood pressure > 105 mmHg at the screening visit
    • History of hypertensive emergency or encephalopathy within 6 months of study treatment
    • Deep venous thrombosis or pulmonary embolism within 3 months of study treatment
  • Major surgery within 4 weeks of study treatment; subjects with clinically relevant ongoing complications from prior surgery are not eligible

  • History of gastrointestinal disorders (medical disorders or extensive surgery) which may interfere with the absorption of the study drug

  • Patient unable to swallow orally administered medication

  • History of bowel obstruction within 1 month of study treatment

  • History of abdominal fistula, intra-abdominal abscess, or gastrointestinal perforation within the 3 months of study treatment

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or radium-223

  • Participants receiving strong CYP3A4/5 inducers or inhibitors are ineligible; dihydropyridine calcium-channel blockers are permitted for management of hypertension; the required washout period prior to starting olaparib is 2 weeks for CYP3A inhibitors; the required washout period prior to starting olaparib is 4 weeks for enzalutamide or phenobarbital and 3 weeks for other CYP3A inducers

  • Patients with known active hepatitis (i.e. hepatitis B or C) infection

  • Patients with myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML

  • Patient having received prior allogenic bone marrow transplant or double umbilical cord blood transplantation

  • Individuals with a history of a different malignancy are ineligible except for the following circumstances:

    • Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy, or
    • Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: superficial bladder cancer, basal cell or squamous cell carcinoma of the skin

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Phase I (radium Ra 223 dichloride, olaparib)

Patients in Phase I receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

Correlative studies

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Given PO

다른 이름들:
  • 린파자
  • AZD2281
  • AZD-2281
  • KU-0059436
  • PARP 억제제 AZD2281
  • KU0059436
  • 올라닙
  • 올라파릭스
  • 쿠 0059436

Undergo tissue biopsy

다른 이름들:
  • 비엑스
  • 생검_유형
  • 생검

Given IV

다른 이름들:
  • 알파라딘
  • 베이 88-8223
  • 베이88-8223
  • 라듐 223 이염화물
  • 라듐 RA-223 이염화물
  • 라듐-223 이염화물
  • 조피고
  • 라듐-223 염화물
실험적: Phase II Arm I (radium Ra 223 dichloride, olaparib)

Patients in Phase II Arm I receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

Correlative studies

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Given PO

다른 이름들:
  • 린파자
  • AZD2281
  • AZD-2281
  • KU-0059436
  • PARP 억제제 AZD2281
  • KU0059436
  • 올라닙
  • 올라파릭스
  • 쿠 0059436

Undergo tissue biopsy

다른 이름들:
  • 비엑스
  • 생검_유형
  • 생검

Given IV

다른 이름들:
  • 알파라딘
  • 베이 88-8223
  • 베이88-8223
  • 라듐 223 이염화물
  • 라듐 RA-223 이염화물
  • 라듐-223 이염화물
  • 조피고
  • 라듐-223 염화물
실험적: Phase II Arm II (radium Ra 223 dichloride)

Patients in Phase 2 Arm II receive radium Ra 223 dichloride as in Arm I. Patients with radiographic progression may crossover to Arm I. If patients have already completed all 6 infusions of radium, they will receive monotherapy with olaparib. If they have not yet completed all 6 radium-223 infusion, they will continue radium-223 infusion until completion and receive concurrent treatment with olaparib. Patients also undergo CT or MRI as well as blood sample collection and a tissue biopsy during screening and on study.

Correlative studies

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Undergo blood sample collection

다른 이름들:
  • 생물학적 샘플 수집
  • 생체 표본 수집
  • 표본 수집
  • 샘플 수집

Undergo CT

다른 이름들:
  • CT
  • 고양이
  • 고양이 스캔
  • 컴퓨터 축 단층 촬영
  • 전산화 단층 촬영
  • CT 스캔
  • 단층 촬영
  • 컴퓨터 축 단층 촬영(시술)
  • 컴퓨터 단층촬영(CT) 스캔
  • 진단 CAT 스캔
  • 진단 CAT 스캔 서비스 유형

Undergo MRI

다른 이름들:
  • MRI
  • 자기 공명
  • 자기공명영상 스캔
  • 의료영상, 자기공명 / 핵자기공명
  • 씨
  • MR 이미징
  • MRI 검사
  • NMR 이미징
  • NMRI
  • 핵자기공명영상
  • 자기공명영상(MRI)
  • SMRI
  • 자기공명영상(시술)
  • 구조적 MRI

Undergo tissue biopsy

다른 이름들:
  • 비엑스
  • 생검_유형
  • 생검

Given IV

다른 이름들:
  • 알파라딘
  • 베이 88-8223
  • 베이88-8223
  • 라듐 223 이염화물
  • 라듐 RA-223 이염화물
  • 라듐-223 이염화물
  • 조피고
  • 라듐-223 염화물

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Phase I: Maximum Tolerated Dose
기간: 56 days

Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223 dichloride (radium-223). (Phase I)

56 days
Phase II: Radiographic Progression-free Survival (rPFS)
기간: From randomization to date of radiographic progression or death due to any cause, whichever occurs first, or censored at the date of last disease assessment. Up to approximately 2 years

Radiographic progression is defined by Prostate Cancer Working Group 3 criteria for bone metastases and RECIST version 1.1 for non-bone metastases. Median rPFS will be estimated using the Kaplan-Meier method by treatment arm. A stratified Cox proportional hazards regression model will estimate the rPFS treatment hazard ratio with 80% 2-sided confidence intervals (CIs). Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions",

From randomization to date of radiographic progression or death due to any cause, whichever occurs first, or censored at the date of last disease assessment. Up to approximately 2 years

2차 결과 측정

결과 측정
측정값 설명
기간
Phase II: rPFS in Patients Without Prior Docetaxel
기간: Up to approximately 2 years after randomization

Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

Up to approximately 2 years after randomization
Phase II: rPFS in Patients With Prior Docetaxel
기간: Up to approximately 2 years after randomization

Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

Up to approximately 2 years after randomization
Phase II: rPFS in Patients With ≤ 20 Bone Lesions
기간: Up to approximately 2 years after randomization

Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

Up to approximately 2 years after randomization
Phase II: rPFS in Patients With > 20 Bone Lesions
기간: Up to approximately 2 years after randomization

Median rPFS will be estimated using the Kaplan-Meier method by treatment arm.

Up to approximately 2 years after randomization
Phase II: Overall Survival (OS)
기간: From randomization to the date of death due to any cause, or censored at the date of last follow-up, assessed up to 3.5 years

Phase II: Median OS will be estimated using the method of Kaplan-Meier.

From randomization to the date of death due to any cause, or censored at the date of last follow-up, assessed up to 3.5 years

기타 결과 측정

결과 측정
측정값 설명
기간
Phase II: rPFS in Patients Without Homologous Recombination Deficiency
기간: Up to approximately 2 years after randomization

rPFS in patients without homologous recombination deficiency

Up to approximately 2 years after randomization
Phase II: rPFS in Patients With Homologous Recombination Deficiency
기간: Up to approximately 2 years after randomization

rPFS in patients with homologous recombination deficiency

Up to approximately 2 years after randomization
Phase II: Prostate Specific Antigen (PSA) Response
기간: Up to approximately 2 years after randomization

Number of participants with prostate specific antigen (PSA) response defined as PSA ≥50% decrease from baseline

Up to approximately 2 years after randomization
Phase II: Alkaline Phosphatase (ALP) Response
기간: Up to approximately 2 years after randomization

Alkaline phosphatase (ALP) response defined as ≥30% decrease from baseline.

Up to approximately 2 years after randomization
Phase II: Symptomatic Skeletal Event (SSE)
기간: Up to approximately 2 years after randomization

Symptomatic skeletal event (SSE) defined as pathologic bone fracture, spinal cord compression, or radiation therapy to bone.

Up to approximately 2 years after randomization
Phase II: Incidence of Grade 3 or Higher Treatment Related Adverse Events (TrAE)
기간: Up to approximately 2 years after randomization

Incidence of grade 3 or higher treatment related adverse events (TrAE)

Up to approximately 2 years after randomization

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

수사관

  • 수석 연구원: Rana R McKay, Yale University Cancer Center LAO

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2019년 2월 4일

기본 완료 (실제)

2025년 3월 31일

연구 완료 (추정된)

2027년 2월 16일

연구 등록 날짜

최초 제출

2017년 10월 20일

QC 기준을 충족하는 최초 제출

2017년 10월 20일

처음 게시됨 (실제)

2017년 10월 23일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 13일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 11일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • NCI-2017-01920
  • UM1CA186689 (미국 NIH 보조금/계약)
  • NCI-2017-01920 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
  • 10096 (기타 식별자: CTEP)
  • 10096 (기타 식별자: Yale University Cancer Center LAO)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .